APA

Dreicer R., MacLean D., Suri A., Stadler W. M., Shevrin D., Hart L., MacVicar G. R., Hamid O., Hainsworth J., Gross M. E., Shi Y., Webb I. J. & Agus D. B. (20141028). Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Dreicer Robert, MacLean David, Suri Ajit, Stadler Walter M, Shevrin Daniel, Hart Lowell, MacVicar Gary R, Hamid Omid, Hainsworth John, Gross Mitchell E, Shi Yuanjun, Webb Iain J and Agus David B. 20141028. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Dreicer R., MacLean D., Suri A., Stadler W. M., Shevrin D., Hart L., MacVicar G. R., Hamid O., Hainsworth J., Gross M. E., Shi Y., Webb I. J. and Agus D. B. (20141028). Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Dreicer Robert, MacLean David, Suri Ajit, Stadler Walter M, Shevrin Daniel, Hart Lowell, MacVicar Gary R, Hamid Omid, Hainsworth John, Gross Mitchell E, Shi Yuanjun, Webb Iain J and Agus David B. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20141028.